Previous 10 | Next 10 |
2023-03-09 23:19:05 ET Lineage Cell Therapeutics, Inc. (LCTX) Q4 2022 Earnings Conference Call March 09, 2023, 04:30 PM ET Company Participants Ioana Hone - Head of IR Brian Culley - CEO Jill Howe - Chief Financial Officer Gary Hogge - SVP, Clinical and Medic...
2023-03-09 16:03:11 ET Lineage Cell Therapeutics press release ( NYSE: LCTX ): FY GAAP EPS of -$0.15 in-line. Revenue of $14.7M (+238.7% Y/Y) misses by $0.63M . For further details see: Lineage Cell Therapeutics GAAP EPS of -$0.15 in-line, revenue of $14.7M m...
Phase 2a Clinical Study of RG6501 (OpRegen ® ) in Patients with GA Secondary to AMD Initiated by Genentech, a Member of the Roche Group Submitted RMAT and Pre-IND Materials to Support OPC1 and VAC2 Programs in Spinal Cord Injury and Oncology, Respectively Launched Two New...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from imaging analyses of structural changes in addition to visual data from a Phase 1/2a clinical stu...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its fourth quarter and full year 2022 financial and operating results on Thursday, March 9, 20...
Lineage Cell Therapeutics ( NYSE: LCTX ) and Eterna Therapeutics ( NASDAQ: ERNA ) signed an option and license agreement to develop novel beta 2 microglobulin (B2M)-deficient induced pluripotent stem cell (iPSC) lines, which Lineage will evaluate for developing differentiated cell...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX ), a clinical-stage biotechnology company developing allogeneic cell therapies to replace and restore specific cell types of the human body, today announced that it has entered into an exclusive option and license agreement (the ...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today provided an update on its auditory neuronal cell therapy program (ANP1), for the treatment of hearing loss, with an initial ...
Summary Lineage Cell Therapeutics' cellular treatment for dry age-related macular degeneration has been very successful in early clinical trials. There does not seem to be any serious competition facing Lineage's AMD treatment. Hoffmann-La Roche has taken over responsibility for con...
Fireside Chat with BTIG Research Scheduled for November 29, 2022 at 12:00pm Eastern Panel Hosted by Cantor Research Scheduled for December 8, 2022 at 1:45pm Eastern Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology...
News, Short Squeeze, Breakout and More Instantly...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company has been added as a member of the broad-market Russell 3000 ® Index, effective after...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company’s CEO, Brian M. Culley, will present at the 2024 BIO International Convention , on Tue...
Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins Clinical Session Expanded to Include Neuralink Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical Lineage Cell Therapeutics, Inc. (NYSE America...